Cambridge Investment Research Advisors
MIRO

Cambridge Investment Research Advisors’s Miromatrix Medical Inc. Common Stock MIRO Stock Holding History

Cambridge Investment Research Advisors’s Portfolio MIRO Stock Details MIRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-66,900
Closed -$267K – 3181
2022
Q2 		$267K Sell
66,900
-1,500
-2% -$5.75K ﹤0.01% 2487
2022
Q1 		$271K Buy
68,400
+32,000
+88% +$119K ﹤0.01% 2630
2021
Q4 		$171K Buy
+36,400
New +$258K ﹤0.01% 2933

Other funds holding MIRO

GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $406M AUM 164.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SFP
Sweet Financial Partners Fairmont, Minnesota $462M AUM 26.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LWAM
Legacy Wealth Asset Management Woodbury, Minnesota $456M AUM 35.19% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Cambridge Investment Research Advisors's MIRO Position: Q3 2022 in Review

Cambridge Investment Research Advisors sold out of Miromatrix Medical Inc. Common Stock (MIRO) in Q3 2022, closing a stake of 66,900 shares — an estimated $267K sold.

Cambridge Investment Research Advisors first reported a position in MIRO in Q4 2021 and held it in 3 quarters. The position peaked at $271K in Q1 2022. 22 funds tracked by Wall St. Rank hold MIRO as of Q3 2022.

  • Cambridge Investment Research Advisors reported no remaining Miromatrix Medical Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 66,900 Miromatrix Medical Inc. Common Stock shares in Q3 2022, an estimated $267K.
  • Cambridge Investment Research Advisors first reported a position in Miromatrix Medical Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Cambridge Investment Research Advisors's Miromatrix Medical Inc. Common Stock position peaked at $271K in Q1 2022.
  • 22 funds tracked by Wall St. Rank held Miromatrix Medical Inc. Common Stock as of Q3 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2022, filed 17 Oct 2022.